First-line gefitinib combined with simplified FOLFOX-6 in patients with epidermal growth factor receptor-positive advanced colorectal cancer

摘要: 3659 Background: The orally active epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, gefitinib (IRESSA) shows promising activity in several tumor types. Preclinical studies suggest has synergistic combination with oxaliplatin colorectal cancer (CRC) cells. This Phase II multicenter study evaluated combined FOLFOX-6 as first-line treatment patients (pts) EGFR-positive advanced CRC. Methods: Pts received 250 mg/day simplified every 2 weeks for ≥8 order to be evaluable response. Treatment was continued until progressive disease (PD), unacceptable toxicity, or withdrawal. clinical benefit after up a maximum of 10 courses could continue monotherapy. Tumor assessment (CT scan) by RECIST made at baseline and 4 cycles. All adverse events (AEs) were assessed NCI-CTC. Serum EGFR assessment. Results: 47/49 pts met the entry criteria: 21 ...